Cancer statistics: Current diagnosis and treatment of pancreatic cancer in Shanghai, China

Cancer Letters

Volumn 346, Issue 2, 2014, Pages 273-277

  Long, Jiang ^a,b   Luo, Guo pei ^a,b   Xiao, Zhi wen ^a,b   Liu, Zu qiang ^a,b   Guo, Meng ^a,b   Liu, Liang ^a,b   Liu, Chen ^a,b   Xu, Jin ^a,b   Gao, Yu tang ^d   Zheng, Ying ^e   Wu, Chunxiao ^e   Ni, Quan xing ^a,b   Li, Min ^a,b,c   Yu, Xianjun ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d SHANGHAI CANCER INSTITUTE   (China)

^e Shanghai Center for Disease Control and Prevention   (China)

Author keywords

Pancreatic cancer; Prognosis; Shanghai; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STATISTICS; CANCER SURGERY; CHINA; COMPUTER ASSISTED TOMOGRAPHY; CYTODIAGNOSIS; ENDOSCOPIC ECHOGRAPHY; FEMALE; HIGH VOLUME HOSPITAL; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PANCREAS CANCER; POPULATION RESEARCH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; AGE; CASE CONTROL STUDY; CLINICAL TRIAL; INCIDENCE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PANCREATIC NEOPLASMS; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; CASE-CONTROL STUDIES; CHINA; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SEX FACTORS;

EID: 84896104787     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.01.004     Document Type: Article

References (35)

1. Li D., Xie K., Wolff R., Abbruzzese J.L. Pancreatic cancer. Lancet 2004, 363:1049-1057.
2. Shi S., Yao W., Xu J., Long J., Liu C., Yu X. Combinational therapy: new hope for pancreatic cancer?. Cancer Lett. 2012, 317:127-135.
3. L. Liu, H.X. Xu, W.Q. Wang, C.T. Wu, T. Chen, Y. Qin, C. Liu, J. Xu, J. Long, B. Zhang, Y.F. Xu, Q.X. Ni, M. Li, X.J. Yu, Cavin-1 is essential for the tumor-promoting effect of caveolin-1 and enhances its prognostic potency in pancreatic cancer, Oncogene, 2013. (Epub ahead of print). doi:10.1038/onc.2013.223.
4. Li Y., Kong D., Ahmad A., Bao B., Sarkar F.H. Pancreatic cancer stem cells: emerging target for designing novel therapy. Cancer Lett. 2013, 338:94-100.
5. Braat H., Bruno M., Kuipers E.J., Peppelenbosch M.P. Pancreatic cancer: promise for personalised medicine?. Cancer Lett. 2012, 318:1-8.
6. Guo X., Cui Z. Current diagnosis and treatment of pancreatic cancer in China. Pancreas 2005, 31:13-22.
7. Weiderpass E., Partanen T., Kaaks R., Vainio H., Porta M., Kauppinen T., Ojajarvi A., Boffetta P., Malats N. Occurrence, trends and environment etiology of pancreatic cancer. Scand. J. Work Environ. Health 1998, 24:165-174.
8. Ghadirian P., Lynch H.T., Krewski D. Epidemiology of pancreatic cancer: an overview. Cancer Detect. Prev. 2003, 27:87-93.
9. Lowenfels A.B., Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract. Res. Clin. Gastroenterol. 2006, 20:197-209.
10. Iodice S., Gandini S., Maisonneuve P., Lowenfels A.B. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch. Surg. 2008, 393:535-545.
11. Ji B.T., Chow W.H., Dai Q., McLaughlin J.K., Benichou J., Hatch M.C., Gao Y.T., Fraumeni J.F. Cigarette smoking and alcohol consumption and the risk of pancreatic cancer: a case-control study in Shanghai, China. Cancer Causes Control 1995, 6:369-376.
12. Wang J., Zhang W., Sun L., Yu H., Ni Q.X., Risch H.A., Gao Y.T. Green tea drinking and risk of pancreatic cancer: a large-scale, population-based case-control study in urban Shanghai. Cancer Epidemiol. 2012, 36:e354-e358.
13. R. Roshani, F. McCarthy, T. Hagemann, Inflammatory cytokines in human pancreatic cancer, Cancer Lett. 345 (2014) 157-163.
14. Gocho T., Uwagawa T., Furukawa K., Haruki K., Fujiwara Y., Iwase R., Misawa T., Ohashi T., Yanaga K. Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-kappaB activation for pancreatic cancer. Cancer Lett. 2013, 333:89-95.
15. S. Fukushige, A. Horii, Road to early detection of pancreatic cancer: attempts to utilize epigenetic biomarkers, Cancer Lett. 342 (2014) 231-237.
16. Yang J., Zhang Y., Cui X., Yao W., Yu X., Cen P., Hodges S.E., Fisher W.E., Brunicardi F.C., Chen C., Yao Q., Li M. Gene profile identifies zinc transporters differentially expressed in normal human organs and human pancreatic cancer. Curr. Mol. Med. 2013, 13:401-409.
17. Cheng H., Li J., Liu C., Yao W., Xu Y., Frank T.S., Cai X., Shi S., Lu Y., Qin Y., Liu L., Xu J., Long J., Ni Q.X., Li M., Yu X.J. Profilin1 sensitizes pancreatic cancer cells to irradiation by inducing apoptosis and reducing autophagy. Curr. Mol. Med. 2013, 13:1368-1375.
18. Baxter N.N., Whitson B.A., Tuttle T.M. Trends in the treatment and outcome of pancreatic cancer in the United States. Ann. Surg. Oncol. 2007, 14:1320-1326.
19. Cunningham D., Chau I., Stocken D.D., Valle J.W., Smith D., Steward W., Harper P.G., Dunn J., Tudur-Smith C., West J., Falk S., Crellin A., Adab F., Thompson J., Leonard P., Ostrowski J., Eatock M., Scheithauer W., Herrmann R., Neoptolemos J.P. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 2009, 27:5513-5518.
20. Neoptolemos J.P., Dunn J.A., Stocken D.D., Almond J., Link K., Beger H., Bassi C., Falconi M., Pederzoli P., Dervenis C., Fernandez-Cruz L., Lacaine F., Pap A., Spooner D., Kerr D.J., Friess H., Buchler M.W. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001, 358:1576-1585.
21. Gong Z., Holly E.A., Bracci P.M. Survival in population-based pancreatic cancer patients: San Francisco Bay area, 1995-1999. Am. J. Epidemiol. 2011, 174:1373-1381.
22. Luo G., Long J., Zhang B., Liu C., Xu J., Ni Q., Yu X. Stroma and pancreatic ductal adenocarcinoma: an interaction loop. Biochim. Biophys. Acta 1826, 2012:170-178.
23. Zhang Y., Yang J., Cui X., Chen Y., Zhu V.F., Hagan J.P., Wang H., Yu X., Hodges S.E., Fang J., Chiao P.J., Logsdon C.D., Fisher W.E., Brunicardi F.C., Chen C., Yao Q., Fernandez-Zapico M.E., Li M. A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth. EMBO Mol. Med. 2013, 5:1322-1334.
24. N. Howlader, M. Krapcho, N. Neyman, R. Aminou, W Waldron, S.F. Altekruse, C.L. Kosary, J. Ruhl, Z. Tatalovich, H. Cho, A. Mariotto, M.P. Eisner, D.R. Lewis, H.S. Chen, E.J. Feuer, K.A. Cronin (Eds.), SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute, Bethesda, MD, 2012.
25. Shaib Y.H., Davila J.A., El-Serag H.B. The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol. Ther. 2006, 24:87-94.
26. Callery M.P., Chang K.J., Fishman E.K., Talamonti M.S., William Traverso L., Linehan D.C. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann. Surg. Oncol. 2009, 16:1727-1733.
27. Micames C., Jowell P.S., White R., Paulson E., Nelson R., Morse M., Hurwitz H., Pappas T., Tyler D., McGrath K. Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest. Endosc. 2003, 58:690-695.
28. Eloubeidi M.A., Chen V.K., Eltoum I.A., Jhala D., Chhieng D.C., Jhala N., Vickers S.M., Wilcox C.M. Endoscopic ultrasound-guided fine needle aspiration biopsy of patients with suspected pancreatic cancer: diagnostic accuracy and acute and 30-day complications. Am. J. Gastroenterol. 2003, 98:2663-2668.
29. Conlon K.C., Klimstra D.S., Brennan M.F. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann. Surg. 1996, 223:273-279.
30. Neoptolemos J.P., Stocken D.D., Friess H., Bassi C., Dunn J.A., Hickey H., Beger H., Fernandez-Cruz L., Dervenis C., Lacaine F., Falconi M., Pederzoli P., Pap A., Spooner D., Kerr D.J., Buchler M.W. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 2004, 350:1200-1210.
31. Ni X., Yang J., Li M. Imaging-guided curative surgical resection of pancreatic cancer in a xenograft mouse model. Cancer Lett. 2012, 324:179-185.
32. Zhang B., Xu J., Liu C., Long J., Liu L., Xu Y., Wu C., Luo G., Ni Q., Li M., Yu X. Application of "papillary-like main pancreatic duct invaginated" pancreaticojejunostomy for normal soft pancreas cases. Sci. Rep. 2013, 3:2068.
33. Jin C., Yao L., Long J., Fu D.L., Yu X.J., Xu J., Yang F., Ni Q.X. Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma. Chin. Med. J. (Engl.) 2009, 122:284-290.
34. Liu C., Long J., Liu L., Xu J., Zhang B., Yu X., Ni Q. Pancreatic stump-closed pancreaticojejunostomy can be performed safely in normal soft pancreas cases. J. Surg. Res. 2012, 172:e11-e17.
35. Pedrazzoli S., DiCarlo V., Dionigi R., Mosca F., Pederzoli P., Pasquali C., Kloppel G., Dhaene K., Michelassi F. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann. Surg. 1998, 228:508-517.